References
- 1. Mahlapuu M, Håkansson J, Ringstad L, Björn C. Antimicrobial Peptides: An Emerging Category of Therapeutic Agents. Front Cell Infect Microbiol. 2016;6:194.10.3389/fcimb.2016.00194
- 2. Zhang L-J, Gallo RL. Antimicrobial peptides. Curr Biol. 2016 Jan 11;26(1):R14-9.10.1016/j.cub.2015.11.017
- 3. Bahar A, Ren D, Bahar AA, Ren D. Antimicrobial Peptides. Pharmaceuticals. 2013 Nov 28;6(12):1543–75.10.3390/ph6121543
- 4. Fjell CD, Hiss JA, Hancock REW, Schneider G. Designing antimicrobial peptides: Form follows function. Nat Rev Drug Discov. 2012;11:37–51.10.1038/nrd3591
- 5. Lakshmaiah Narayana J, Chen JY. Antimicrobial peptides: Possible anti-infective agents. Peptides. 2015;72:88–94.10.1016/j.peptides.2015.05.012
- 6. Li Y, Xiang Q, Zhang Q, Huang Y, Su Z. Overview on the recent study of antimicrobial peptides: origins, functions, relative mechanisms and application. Peptides. 2012;37:207–15.10.1016/j.peptides.2012.07.001
- 7. Hancock REW, Sahl H-G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol. 2006;24(12):1551–7.10.1038/nbt1267
- 8. Kosikowska P, Lesner A. Antimicrobial peptides (AMPs) as drug candidates: a patent review (2003–2015). Expert Opin Ther Pat. 2016;26(6):689–702.10.1080/13543776.2016.1176149
- 9. Fox JL. Antimicrobial peptides stage a comeback. Nat Biotechnol. 2013;31(5):379–82.10.1038/nbt.2572
- 10. Park CB, Kim MS, Kim SC. A novel antimicrobial peptide from Bufo bufo gargarizans. Biochem Biophys Res Commun. 1996;218:408–13.10.1006/bbrc.1996.0071
- 11. Park CB, Kim HS, Kim SC. Mechanism of action of the antimicrobial peptide buforin II: Buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem Biophys Res Commun. 1998;244:253–7.10.1006/bbrc.1998.8159
- 12. Uyterhoeven ET, Butler CH, Ko D, Elmore DE. Investigating the nucleic acid interactions and antimicrobial mechanism of buforin II. FEBS Lett. 2008;582:1715–8.10.1016/j.febslet.2008.04.036
- 13. Lee HS, Park CB, Kim JM, Jang SA, Park IY, Kim MS, et al. Mechanism of anticancer activity of buforin IIb, a histone H2A-derived peptide. Cancer Lett. 2008;271:47–55.10.1016/j.canlet.2008.05.041
- 14. Marqus S, Pirogova E, Piva TJ. Evaluation of the use of therapeutic peptides for cancer treatment. J Biomed Sci. 2017;24:21.10.1186/s12929-017-0328-x
- 15. Salamon P, Miklóssy I, Albert B, Korodi M, Nagy K, Bakos I, et al. Heterologous Expression and Purification of Recombinant Proapoptotic Human Protein Smac/Diablo with EGFP as Fusion Partner. Stud Univ Babeș-Bolyai Chem. 2017 Jun;62(2):333–45.10.24193/subbchem.2017.2.26
- 16. Boda FA, Salamon P, Orbán C, Berta L, Curticăpean A, Gâz Șerban A, et al. Heterologous expression and purification of recombinant crotoxin B, the phospholipase A2 subunit of crotoxin. Stud Univ Babes-Bolyai Chem. 2018;10.24193/subbchem.2018.1.01
- 17. Wang Q, Zhu F, Xin Y, Liu J, Luo L, Yin Z. Expression and purification of antimicrobial peptide buforin IIb in Escherichia coli. Biotechnol Lett. 2011;33:2121–6.10.1007/s10529-011-0687-4